First-in-man implantation of the Tricento® transcatheter heart valve for the treatment of severe tricuspid regurgitation.

Here we describe the first implantation of the novel bicavally anchored Tricento® transcatheter heart valve via transvenous transfemoral access in a 74-year-old woman with severe tricuspid regurgitation and holosystolic hepatic vein backflow. Following successful implantation, caval vein regurgitant volume was reduced leading to symptomatic and clinical improvement at 3 months follow-up. The Tricento® device represents a promising, novel therapeutic option for patients with severe tricuspid regurgitation that are not candidates for open heart surgery.